Engineered exosomes from different sources for cancer-targeted therapy.

Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C. · 2023

Read Engineered exosomes from different sources for cancer-targeted therapy. by Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10017761.txt.

Introduction

Zhang and colleagues review engineered exosomes as a tool for targeted cancer treatment in a 2023 paper. Exosomes are tiny parcels that cells release to send signals to other cells. Researchers can load them with drugs and add surface features that steer them toward tumors.

The review covers exosomes from different cell sources and how each source affects their use. It explains how loading and steering are done in the lab. It also weighs safety and the steps left before clinic use. The paper maps a lively field in drug delivery.

Catalog record

CREATORZhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10017761

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Engineered exosomes from different sources for cancer-targeted therapy By Menghui Zhang, Shengyun Hu, Lin Liu, Pengyuan Dang, Yang Liu, Zhenqiang Sun, Bingbing Qiao, Chengzeng Wang Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01382-y ABSTRACT Abstract Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient therapeutic tool for various diseases. Engineered exosomes are the sort of exosomes modified with surface decoration and internal therapeutic molecules. After appropriate modification, engineered exosomes are able to deliver antitumor drugs to tumor sites efficiently and precisely with fewer treatment-related adverse effects. However, there still exist many challenges for the clinical translation of engineered exosomes. For instance, what sources and modification strategies could endow exosomes with the most efficient antitumor activity is still poorly understood. Additionally, how to choose appropriately engineered exosomes in different antitumor therapies is another unresolved problem. In this review, we summarized the characteristics of engineered exosomes, especially the spatial and temporal properties. Additionally, we concluded the recent advances in engineered exosomes in the cancer fields, including the sources, isolation technologies, modification strategies, and labeling and imaging methods of engineered exosomes. Furthermore, the applications of engineered exosomes in different antitumor therapies were summarized, such as photodynamic therapy, gene therapy, and immunotherapy. Consequently, the above provides the cancer researchers in this community with the latest ideas on engineered exosome modification and new direction of new drug development, which is prospective to accelerate the clinical translation of engineered exosomes for cancer-targeted therapy. Subject terms: Drug development, Nanobiotechnology INTRODUCTION In 1946, Chargaff and West found a kind of clotting factor similar to the thromboplastic protein when they study anemia and hemophilia,1 which was considered the beginning of the field of extracellular vesicles (EV) biology. About 20 years later, Peter Wolf published electron microscopy images of these particles.2 In 1974, Nunez and Gershon proved the existence of small (1–10 nm) extracellular vesicles in the bat thyroid gland.3 In 1983, two studies proved the release of intraluminal vesicles from the cell, and defined them as exosomes, which were interpreted as the origins of the field.4,5 In addition to the discovery of exosomes, studies about the hallmarks of EVs also emerged. Rose Johnstone described exosomes as ‘waste disposal mechanisms’6 and that exosomes from reticulocytes were enzymatically active7 in 1990s. Meanwhile, several studies reported the quantification of exosomes, illustrating altered exosome numbers in plenty diseases.8–10 In the early 21st century, the increased interest in EVs led to the exponential growth of the field. For example, cytokines were found to be shed via exosomes in 2001.11 Two years later, immune cell-derived exosomes were proven to modulate the function of the immune system.12,13 In 2011, the International Society for Extracellular Vesicles (ISEV) was founded, which promoted the innovation and application of exosomes extremely. In 2014, the publication of ‘Minimal Information for Studies of EVs’ (MISEV) guidelines was an important event in the standardization of this field.14 In 2019, researchers detected single exosomes using new techniques,15–17 indicating the imaging of exosomes entered the era of single exosomes in vivo (Fig. 1). [Figure: Timeline of exosomes milestones. In 1946, the finding of one clotting factor, similar to the thromboplastic protein, by Chargaff was considered as the beginning of the field of extracellular vesicles (EVs). The EV field emerged the exponential growth in the early 21st century. In 2011, the foundation of the International Society for Extracellular Vesicles (ISEV) promoted the development of exosomes extremely. In 2019, the imaging of exosomes entered the era of single exosomes in vivo] Given the development and success of exosome research, engineered exosomes are attracting increasing attention, especially in cancer fields, due to their spatial and temporal targeting ability. In 2005, the Amigorena lab proved that exosomes from dendritic cells could eradicate tumors when loaded with tumor peptides18 and consequently led to clinical trials.19 Although natural exosomes can deliver antitumor drugs, they mostly retain in the liver or spleen rather than in tumor tissue. Additionally, the therapeutic efficacy is attenuated due to the heterogeneity and complicated components of natural EVs.20 Hence, engineering technologies confer exosomes more specifically targeting property and clinical translation potential. Nowadays, engineering strategies are various and different. It is generally divided into four categories: biological (targeting peptides), immunological (antibodies), physical (magnetic particles), and chemical modification (sodium bicarbonate). However, each engineering method has its own advantages and disadvantages and the ‘one-size-fits-all’ engineering approach does not exist yet. Hence, investigators chose to integrate multiple strategies to enhance the targeting ability of engineered exosomes. For instance, photo-activatable silencing extracellular vesicles (PASEVs) were loaded with siRNA against PAK4 (siPAK4) and photo-activatable reactive oxygen species (ROS)-sensitive polymer to form the nanocomplex core. Furthermore, the nanocomplex cores were camouflaged by extracellular vesicles from M1 macrophages. ROS-responsive release of siPAK4 not only silenced PAK4, but also modulated TME via immunogenic phototherapy21. Therefore, cancer immunotherapy was sensitized. In addition to strengthening the efficiency of antitumor therapies, engineered exosomes, as a new drug delivery platform, might alleviate the side effects during therapies, such as chemotherapy and radiotherapy. Injecting free chemotherapeutic intravenously is the mainstream of systemic therapy for cancers. However, due to the low targeting ability, this approach generally causes various therapy-related adverse effects (TRAEs) including leukocytopenia, hypothyroidism, and ALT or AST elevation. In order to address the above issues, engineered exosomes as a new drug delivery platform have attracted increasing attention. For example, melanoma-derived, doxorubicin (DOX)-loaded, and targeted peptide-decorated exosomes were developed to amplify the specific characteristics. The engineered exosomes preferentially target disease sites coupled with minimizing systemic off-target issues22. This review encapsulated the patterns of engineered exosomes and recent advances in the techniques of engineered exosomes. Additionally, the latest preclinical trials about the engineered exosome-based therapies were summarized, which were potential and beneficial for the translation of engineered exosomes in the future. (Fig. 2). [Figure: Schematic illustration of the engineered exosomes exhibiting antitumor effects on preclinical models. After intravenous injection, the engineered exosomes carrying the therapeutic molecules arrive at the tumor site under the guide of multiple targeting molecules or a magnetic field. Then the chemotherapeutic drugs, such as PTX, the ncRNAs, such as miR-551-3p, immune molecules, such siPDL1, were released into the tumor microenvironment (TME). Thereafter, the internalization of engineered exosomes led to tumor cell death, such as ferroptosis] THE SPATIAL-TEMPORAL PATTERNS OF ENGINEERED EXOSOMES Engineered exosomes target tumor sites spatially The exosomes decorated with specific targeted molecules, including peptides, can achieve more precise therapeutic cargo delivery. The miR-HER2 (human epidermal growth factor receptor 2)-loaded exosomes coated with ligands, which enables them to adhere to HER2 on the surface of human laryngeal carcinoma cells and preferentially enter HER2-positive cells. More importantly, the miR-HER2-loaded exosomes coated with additional peptide trigger more fierce tumoricidal effects than the exosomes without targeted peptide.21 Additionally, the plant-derived exosomes, especially medicinal herbs, also attracted the increasing attention of researchers due to the synergistic effects with low toxicity.22 For example, exosomes-like nanovesicles (ELNVs) derived from Asparagus cochinchinensis (Lour.) Merr. (ACNVs) were found to inhibit hepatocellular carcinoma (HCC) proliferation by activating apoptosis pathway.23 Despite the pronounced antitumor effects of natural ACNVs, the macropinocytosis of mononuclear phagocyte system (MPS), including in the liver and spleen, results in the quick clearance of exosomes in bloodstream and minimal accumulation within tumor area.24 Therefore, researchers decorated ACNVs with

Read the complete text